The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·2 days ago, 04:14 AMINM+1.71%ONCY-0.91%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·Jul 25 at 04:17 AMGENB-6.03%IBRX-0.64%
Consumer Resilience Meets Sector Divergence: A Microcosm for Fed OfficialsGlobal Report·Jul 25 at 04:13 AMKR+2.31%TDC-1.31%
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or StandardTradingView·Jul 24 at 03:43 PMONCY-0.91%
The AI Pivot Pain: Inside monday.com's Layoffs and the Broader Strategic OverhaulsGlobal Report·Jul 24 at 04:13 AMMNDY+5.36%NTNX+3.69%
Columbia Financial's USD 1.7B Raise and Timken's Guidance Hike Lead Mid-2026 Strategic ShiftsGlobal Report·Jul 22 at 04:18 AMCLBK+1.01%TKR-0.34%
Oncolytics Biotech wins FDA Fast Track status for pelareorep in second-line anal cancerPUBT·Jul 20 at 08:08 AMONCY-0.91%
The Divergence of Moats: Physical Infrastructure, Strategic Pivots, and Survival MechanicsGlobal Report·Jul 19 at 04:12 AMWU+0.43%NAK-4.25%
